1. [35020204] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33.
2. [25381395] Moossdorff M, van Roozendaal LM, Strobbe LJ, et al. Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. J Natl Cancer Inst 2014;106.
3. [30265613] Kalli S, Semine A, Cohen S, Naber SP, Makim SS, Bahl M. American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: What the Radiologist Needs to Know. [Review]. Radiographics. 38(7):1921-1933, 2018 Nov-Dec.
4. [28294295] Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: a Cancer Journal for Clinicians. 67(4):290-303, 2017 07 08.
5. [29931426] Kim JY, Lim JE, Jung HH, et al. Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort. Breast Cancer Res Treat. 171(3):737-745, 2018 Oct.
6. [34161138] Stringer-Reasor EM, Elkhanany A, Khoury K, Simon MA, Newman LA. Disparities in Breast Cancer Associated With African American Identity. Am Soc Clin Oncol Educ Book 2021;41:e29-e46.
7. [35713541] Jatoi I, Sung H, Jemal A. The Emergence of the Racial Disparity in U.S. Breast-Cancer Mortality. N Engl J Med 2022;386:2349-52.
8. [25901056] Hahn EE, Tang T, Lee JS, et al. Use of imaging for staging of early-stage breast cancer in two integrated health care systems: adherence with a choosing wisely recommendation. J Oncol Pract. 11(3):e320-8, 2015 May.
9. [32109016] Lupichuk S, Tilley D, Surgeoner B, King K, Joy AA. Unwarranted imaging for distant metastases in patients with newly diagnosed ductal carcinoma in situ and stage I and II breast cancer. Canadian Journal of Surgery. 63(2):E100-E109, 2020 02 28.
10. [17369571] Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol. 2007;25(9):1074-1081.
11. [28535000] Catalano OA, Daye D, Signore A, et al. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast. Int J Oncol. 51(1):281-288, 2017 Jul.
12. [32769814] de Mooij CM, Sunen I, Mitea C, et al. Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients. Nucl Med Commun 2020;41:995-1004.
13. [33651022] Han S, Choi JY. Impact of 18F-FDG PET, PET/CT, and PET/MRI on Staging and Management as an Initial Staging Modality in Breast Cancer: A Systematic Review and Meta-analysis. Clin Nucl Med 2021;46:271-82.
14. [30292261] Lin CY, Lin CL, Kao CH. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis. Eur J Radiol. 107:158-165, 2018 Oct.
15. [33894709] Lu XR, Qu MM, Zhai YN, Feng W, Gao Y, Lei JQ. Diagnostic role of 18F-FDG PET/MRI in the TNM staging of breast cancer: a systematic review and meta-analysis. Ann Palliat Med 2021;10:4328-37.
16. [31660801] Sumkin JH, Berg WA, Carter GJ, et al. Diagnostic Performance of MRI, Molecular Breast Imaging, and Contrast-enhanced Mammography in Women with Newly Diagnosed Breast Cancer. Radiology. 293(3):531-540, 2019 12.
17. [22006539] Kim BS.. Usefulness of breast-specific gamma imaging as an adjunct modality in breast cancer patients with dense breast: a comparative study with MRI. Ann Nucl Med. 26(2):131-7, 2012 Feb.
18. [31166752] Hunt KN, Conners AL, Goetz MP, et al. Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy. AJR Am J Roentgenol. 213(4):932-943, 2019 10.
19. [32374053] Kurland BF, Wiggins JR, Coche A, et al. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16alpha-18F-Fluoro-17beta-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications. Oncologist 2020;25:835-44.
20. [22751517] Akashi-Tanaka S, Sato N, Ohsumi S, et al. Evaluation of the usefulness of breast CT imaging in delineating tumor extent and guiding surgical management: a prospective multi-institutional study. Ann Surg. 256(1):157-62, 2012 Jul.
21. [-3196411] American College of Radiology. ACR–SABI–SAR–SPR PRACTICE PARAMETER FOR THE PERFORMANCE OF COMPUTED TOMOGRAPHY (CT) OF THE ABDOMEN AND COMPUTED TOMOGRAPHY (CT) OF THE PELVIS. Available at: https://gravitas.acr.org/PPTS/GetDocumentView?docId=168+&releaseId=2
22. [15486214] Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004; 233(3):830-849.
23. [26376882] Kim WH, Chang JM, Moon HG, et al. Comparison of the diagnostic performance of digital breast tomosynthesis and magnetic resonance imaging added to digital mammography in women with known breast cancers. Eur Radiol. 26(6):1556-64, 2016 Jun.
24. [30964425] Fontaine M, Tourasse C, Pages E, et al. Local Tumor Staging of Breast Cancer: Digital Mammography versus Digital Mammography Plus Tomosynthesis. Radiology. 291(3):594-603, 2019 06.
25. [25086999] Mercier J, Kwiatkowski F, Abrial C, et al. The role of tomosynthesis in breast cancer staging in 75 patients. Diagn Interv Imaging. 96(1):27-35, 2015 Jan.
26. [23826951] Gruber IV, Rueckert M, Kagan KO, et al. Measurement of tumour size with mammography, sonography and magnetic resonance imaging as compared to histological tumour size in primary breast cancer. BMC Cancer. 13:328, 2013 Jul 05.
27. [27411945] Stein RG, Wollschlager D, Kreienberg R, et al. The impact of breast cancer biological subtyping on tumor size assessment by ultrasound and mammography - a retrospective multicenter cohort study of 6543 primary breast cancer patients. BMC Cancer. 16:459, 2016 07 13.
28. [28055247] Helal MH, Mansour SM, Zaglol M, Salaleldin LA, Nada OM, Haggag MA. Staging of breast cancer and the advanced applications of digital mammogram: what the physician needs to know?. Br J Radiol. 90(1071):20160717, 2017 Mar.
29. [30466027] Marinovich ML, Bernardi D, Macaskill P, Ventriglia A, Sabatino V, Houssami N. Agreement between digital breast tomosynthesis and pathologic tumour size for staging breast cancer, and comparison with standard mammography. BREAST. 43:59-66, 2019 Feb.
30. [22941162] Kapoor NS, Eaton A, King TA, et al. Should breast density influence patient selection for breast-conserving surgery?. Ann Surg Oncol. 20(2):600-6, 2013 Feb.
31. [27920631] Grubstein A, Rapson Y, Morgenstern S, et al. Invasive Lobular Carcinoma of the Breast: Appearance on Digital Breast Tomosynthesis. Breast Care (Basel) 2016;11:359-62.
32. [28516226] Yun SJ, Ryu CW, Rhee SJ, Ryu JK, Oh JY. Benefit of adding digital breast tomosynthesis to digital mammography for breast cancer screening focused on cancer characteristics: a meta-analysis. [Review]. Breast Cancer Research & Treatment. 164(3):557-569, 2017 Aug.Breast Cancer Res Treat. 164(3):557-569, 2017 Aug.
33. [29927337] Marinovich ML, Macaskill P, Bernardi D, Houssami N. Systematic review of agreement between tomosynthesis and pathologic tumor size for newly diagnosed breast cancer and comparison with other imaging tests. Expert Rev Med Devices 2018;15:489-96.
34. [26492903] Hadjiminas DJ, Zacharioudakis KE, Tasoulis MK, et al. Adequacy of diagnostic tests and surgical management of symptomatic invasive lobular carcinoma of the breast. Ann R Coll Surg Engl. 97(8):578-83, 2015 Nov.
35. [30045266] Liu Q, Xing P, Dong H, Zhao T, Jin F. Preoperative assessment of axillary lymph node status in breast cancer patients by ultrasonography combined with mammography: A STROBE compliant article. Medicine (Baltimore). 97(30):e11441, 2018 Jul.
36. [26711795] Pilewskie M, Jochelson M, Gooch JC, Patil S, Stempel M, Morrow M. Is Preoperative Axillary Imaging Beneficial in Identifying Clinically Node-Negative Patients Requiring Axillary Lymph Node Dissection?. J Am Coll Surg. 222(2):138-45, 2016 Feb.
37. [28130619] Barrio AV, Mamtani A, Eaton A, Brennan S, Stempel M, Morrow M. Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?. Ann Surg Oncol. 24(3):645-651, 2017 Mar.
38. [26477029] Botsikas D, Kalovidouri A, Becker M, et al. Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging. Eur Radiol. 26(7):2297-307, 2016 Jul.
39. [26115367] Grueneisen J, Nagarajah J, Buchbender C, et al. Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging. Invest Radiol. 50(8):505-13, 2015 Aug.
40. [27058014] Teixeira SC, Rebolleda JF, Koolen BB, et al. Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I-III Breast Cancer: Comparison With Standard PET/CT. AJR Am J Roentgenol. 206(6):1307-14, 2016 Jun.
41. [21935602] Koolen BB, Vrancken Peeters MJ, Aukema TS, et al. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat. 131(1):117-26, 2012 Jan.
42. [24108553] Ecanow JS, Abe H, Newstead GM, Ecanow DB, Jeske JM. Axillary staging of breast cancer: what the radiologist should know. [Review]. Radiographics. 33(6):1589-612, 2013 Oct.
43. [2910416] Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
44. [31339353] Sasada S, Masumoto N, Kimura Y, et al. Identification of Axillary Lymph Node Metastasis in Patients With Breast Cancer Using Dual-Phase FDG PET/CT. AJR Am J Roentgenol. 213(5):1129-1135, 2019 11.
45. [24866608] Sohn YM, Hong IK, Han K. Role of [18F]fluorodeoxyglucose positron emission tomography-computed tomography, sonography, and sonographically guided fine-needle aspiration biopsy in the diagnosis of axillary lymph nodes in patients with breast cancer: comparison of diagnostic performance. J Ultrasound Med. 33(6):1013-21, 2014 Jun.
46. [28861372] Cortadellas T, Argacha P, Acosta J, et al. Estimation of tumor size in breast cancer comparing clinical examination, mammography, ultrasound and MRI-correlation with the pathological analysis of the surgical specimen. Gland Surg 2017;6:330-35.
47. [33650905] Jochelson MS, Lobbes MBI. Contrast-enhanced Mammography: State of the Art. Radiology. 2021 Apr;299(1):36-48.
48. [24048724] Fallenberg EM, Dromain C, Diekmann F, et al. Contrast-enhanced spectral mammography versus MRI: Initial results in the detection of breast cancer and assessment of tumour size. Eur Radiol. 24(1):256-64, 2014 Jan.
49. [23220903] Jochelson MS, Dershaw DD, Sung JS, et al. Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. Radiology. 266(3):743-51, 2013 Mar.
50. [31017460] Youn I, Choi S, Choi YJ, et al. Contrast enhanced digital mammography versus magnetic resonance imaging for accurate measurement of the size of breast cancer. Br J Radiol. 92(1098):20180929, 2019 Jun.
51. [32000448] Cheung YC, Juan YH, Lo YF, Lin YC, Yeh CH, Ueng SH. Preoperative assessment of contrast-enhanced spectral mammography of diagnosed breast cancers after sonographic biopsy: Correlation to contrast-enhanced magnetic resonance imaging and 5-year postoperative follow-up. Medicine. 99(5):e19024, 2020 Jan.
52. [24986697] Fallenberg EM, Dromain C, Diekmann F, et al. Contrast-enhanced spectral mammography: Does mammography provide additional clinical benefits or can some radiation exposure be avoided?. Breast Cancer Res Treat. 146(2):371-81, 2014 Jul.
53. [28654337] Lee-Felker SA, Tekchandani L, Thomas M, et al. Newly Diagnosed Breast Cancer: Comparison of Contrast-enhanced Spectral Mammography and Breast MR Imaging in the Evaluation of Extent of Disease. Radiology. 2017 Nov;285(2):389-400.
54. [33178931] van Nijnatten TJ, Jochelson MS, Pinker K, et al. Differences in degree of lesion enhancement on CEM between ILC and IDC. BJR Open 2019;1:20180046.
55. [21751044] Miller BT, Abbott AM, Tuttle TM. The influence of preoperative MRI on breast cancer treatment. Ann Surg Oncol. 19(2):536-40, 2012 Feb.
56. [33120285] Elmi A, Conant EF, Kozlov A, et al. Preoperative breast MR imaging in newly diagnosed breast cancer: Comparison of outcomes based on mammographic modality, breast density and breast parenchymal enhancement. Clinical Imaging. 70:18-24, 2021 Feb.
57. [27384241] He H, Plaxco JS, Wei W, et al. Incremental cancer detection using breast ultrasonography versus breast magnetic resonance imaging in the evaluation of newly diagnosed breast cancer patients. Br J Radiol. 89(1065):20160401, 2016 Sep.
58. [19805685] Brennan ME, Houssami N, Lord S, et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol 2009;27:5640-9.
59. [27566960] Choi WJ, Cha JH, Kim HH, Shin HJ, Chae EY. The Accuracy of Breast MR Imaging for Measuring the Size of a Breast Cancer: Analysis of the Histopathologic Factors. Clin Breast Cancer. 16(6):e145-e152, 2016 12.
60. [32536526] Sanderink WBG, Caballo M, Strobbe LJA, et al. Reliability of MRI tumor size measurements for minimal invasive treatment selection in small breast cancers. European Journal of Surgical Oncology. 46(8):1463-1470, 2020 08.
61. [22446897] Shin HC, Han W, Moon HG, et al. Limited value and utility of breast MRI in patients undergoing breast-conserving cancer surgery. Ann Surg Oncol. 19(8):2572-9, 2012 Aug.
62. [28705168] Carin AJ, Moliere S, Gabriele V, et al. Relevance of breast MRI in determining the size and focality of invasive breast cancer treated by mastectomy: a prospective study. World J Surg Oncol. 15(1):128, 2017 Jul 14.
63. [31361209] Mann RM, Cho N, Moy L. Breast MRI: State of the Art. Radiology 2019;292:520-36.
64. [24817517] Gonzalez V, Sandelin K, Karlsson A, et al. Preoperative MRI of the breast (POMB) influences primary treatment in breast cancer: a prospective, randomized, multicenter study. World J Surg. 38(7):1685-93, 2014 Jul.
65. [28445683] Kuhl CK, Strobel K, Bieling H, et al. Impact of Preoperative Breast MR Imaging and MR-guided Surgery on Diagnosis and Surgical Outcome of Women with Invasive Breast Cancer with and without DCIS Component. Radiology. 284(3):645-655, 2017 09.
66. [26387498] Patel BK, Shah NA, Galgano SJ, et al. Does Preoperative MRI Workup Affect Mastectomy Rates and/or Re-excision Rates in Patients with Newly Diagnosed Breast Carcinoma? A Retrospective Review. Breast J. 21(6):604-9, 2015 Nov-Dec.
67. [28712698] Preibsch H, Blumenstock G, Oberlechner E, et al. Preoperative breast MR Imaging in patients with primary breast cancer has the potential to decrease the rate of repeated surgeries. Eur J Radiol. 94:148-153, 2017 Sep.
68. [24848838] Sung JS, Li J, Da Costa G, et al. Preoperative breast MRI for early-stage breast cancer: effect on surgical and long-term outcomes. AJR Am J Roentgenol. 202(6):1376-82, 2014 Jun.
69. [34643778] Sardanelli F, Trimboli RM, Houssami N, et al. Magnetic resonance imaging before breast cancer surgery: results of an observational multicenter international prospective analysis (MIPA). European Radiology. 32(3):1611-1623, 2022 Mar.
70. [20159292] Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet. 375(9714):563-71, 2010 Feb 13.
71. [28589366] Houssami N, Turner RM, Morrow M. Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer. [Review]. Breast Cancer Res Treat. 165(2):273-283, 2017 Sep.
72. [32828998] Amin AL, Sack S, Larson KE, et al. Does the Addition of Breast MRI Add Value to the Diagnostic Workup of Invasive Lobular Carcinoma?. J Surg Res. 257:144-152, 2021 01.
73. [26853509] Bansal GJ, Santosh D, Davies EL. Selective magnetic resonance imaging (MRI) in invasive lobular breast cancer based on mammographic density: does it lead to an appropriate change in surgical treatment?. Br J Radiol. 89(1060):20150679, 2016.
74. [28187373] Brennan ME, McKessar M, Snook K, Burgess I, Spillane AJ. Impact of selective use of breast MRI on surgical decision-making in women with newly diagnosed operable breast cancer. BREAST. 32:135-143, 2017 Apr.
75. [26639066] El Sharouni MA, Postma EL, Menezes GL, et al. High Prevalence of MRI-Detected Contralateral and Ipsilateral Malignant Findings in Patients With Invasive Ductolobular Breast Cancer: Impact on Surgical Management. Clin Breast Cancer. 16(4):269-75, 2016 08.
76. [29388904] Ha SM, Chae EY, Cha JH, Kim HH, Shin HJ, Choi WJ. Breast MR Imaging before Surgery: Outcomes in Patients with Invasive Lobular Carcinoma by Using Propensity Score Matching. Radiology. 287(3):771-777, 2018 Jun.
77. [21460377] Heil J, Buehler A, Golatta M, et al. Do patients with invasive lobular breast cancer benefit in terms of adequate change in surgical therapy from a supplementary preoperative breast MRI?. Ann Oncol. 23(1):98-104, 2012 Jan.
78. [24034548] Muttalib M, Ibrahem R, Khashan AS, Hajaj M. Prospective MRI assessment for invasive lobular breast cancer. Correlation with tumour size at histopathology and influence on surgical management. Clin Radiol. 69(1):23-8, 2014 Jan.
79. [26841281] Parvaiz MA, Yang P, Razia E, et al. Breast MRI in Invasive Lobular Carcinoma: A Useful Investigation in Surgical Planning?. Breast J. 22(2):143-50, 2016 Mar-Apr.
80. [30046588] Selvi V, Nori J, Meattini I, et al. Role of Magnetic Resonance Imaging in the Preoperative Staging and Work-Up of Patients Affected by Invasive Lobular Carcinoma or Invasive Ductolobular Carcinoma. Biomed Res Int. 2018:1569060, 2018.
81. [27087381] Sinclair K, Sakellariou S, Dawson N, Litherland J. Does preoperative breast MRI significantly impact on initial surgical procedure and re-operation rates in patients with screen-detected invasive lobular carcinoma?. Clin Radiol. 71(6):543-50, 2016 Jun.
82. [32863709] Moloney BM, McAnena PF, Ryan EJ, et al. The Impact of Preoperative Breast Magnetic Resonance Imaging on Surgical Management in Symptomatic Patients With Invasive Lobular Carcinoma. Breast Cancer (Auckl) 2020;14:1178223420948477.
83. [30617471] Ha SM, Chae EY, Cha JH, Kim HH, Shin HJ, Choi WJ. Long-term survival outcomes in invasive lobular carcinoma patients with and without preoperative MR imaging: a matched cohort study. Eur Radiol. 29(5):2526-2534, 2019 May.
84. [28053631] Ryu J, Park HS, Kim S, Kim JY, Park S, Kim SI. Preoperative Magnetic Resonance Imaging and Survival Outcomes in T1-2 Breast Cancer Patients Who Receive Breast-Conserving Therapy. J. Breast Cancer. 19(4):423-428, 2016 Dec.
85. [24395846] Houssami N, Turner R, Macaskill P, et al. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol. 32(5):392-401, 2014 Feb 10.
86. [34611701] Gonzalez V, Arver B, Lofgren L, Bergkvist L, Sandelin K, Eriksson S. Impact of preoperative breast MRI on 10-year survival of patients included in the Swedish randomized multicentre POMB trial. BJS Open 2021;5.
87. [35471109] Freitas V, Li X, Amitai Y, et al. Contralateral Breast Screening with Preoperative MRI: Long-Term Outcomes for Newly Diagnosed Breast Cancer. Radiology. 304(2):297-307, 2022 08.
88. [35550807] Le-Petross HT, Slanetz PJ, Lewin AA, et al. ACR Appropriateness Criteria® Imaging of the Axilla. J Am Coll Radiol 2022;19:S87-S113.
89. [28898379] Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 2017;318:918-26.
90. [29381381] Le-Petross HT, McCall LM, Hunt KK, et al. Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). AJR Am J Roentgenol. 210(3):669-676, 2018 Mar.
91. [23515655] Ertan K, Linsler C, di Liberto A, Ong MF, Solomayer E, Endrikat J. Axillary ultrasound for breast cancer staging: an attempt to identify clinical/histopathological factors impacting diagnostic performance. Breast Cancer (Auckl). 7:35-40, 2013.
92. [24455284] Kaur N, Sharma P, Garg A, Tandon A. Accuracy of individual descriptors and grading of nodal involvement by axillary ultrasound in patients of breast cancer. Int J Breast Cancer 2013;2013:930596.
93. [23664535] Elmore LC, Appleton CM, Zhou G, Margenthaler JA. Axillary ultrasound in patients with clinically node-negative breast cancer: which features are predictive of disease?. J Surg Res. 184(1):234-40, 2013 Sep.
94. [24859939] Caudle AS, Kuerer HM, Le-Petross HT, et al. Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol. 21(11):3440-7, 2014 Oct.
95. [18955508] Abe H, Schmidt RA, Kulkarni K, Sennett CA, Mueller JS, Newstead GM. Axillary lymph nodes suspicious for breast cancer metastasis: sampling with US-guided 14-gauge core-needle biopsy--clinical experience in 100 patients. Radiology 2009;250:41-9.
96. [16632729] Alvarez S, Anorbe E, Alcorta P, Lopez F, Alonso I, Cortes J. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol 2006;186:1342-8.
97. [31562691] Upadhyaya VS, Lim GH, Chan EYK, Fook-Chong SMC, Leong LCH. Evaluating the preoperative breast cancer characteristics affecting the accuracy of axillary ultrasound staging. Breast Journal. 26(2):162-167, 2020 02.
98. [23436877] Lee B, Lim AK, Krell J, et al. The efficacy of axillary ultrasound in the detection of nodal metastasis in breast cancer. AJR Am J Roentgenol 2013;200:W314-20.
99. [22972506] Cools-Lartigue J, Sinclair A, Trabulsi N, et al. Preoperative axillary ultrasound and fine-needle aspiration biopsy in the diagnosis of axillary metastases in patients with breast cancer: predictors of accuracy and future implications. Ann Surg Oncol. 20(3):819-27, 2013 Mar.
100. [21597359] Houssami N, Ciatto S, Turner RM, Cody HS 3rd, Macaskill P. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Ann Surg. 254(2):243-51, 2011 Aug.
101. [29279156] Del Riego J, Diaz-Ruiz MJ, Teixido M, et al. The impact of axillary ultrasound with biopsy in overtreatment of early breast cancer. Eur J Radiol. 98:158-164, 2018 Jan.
102. [29972239] Balasubramanian I, Fleming CA, Corrigan MA, Redmond HP, Kerin MJ, Lowery AJ. Meta-analysis of the diagnostic accuracy of ultrasound-guided fine-needle aspiration and core needle biopsy in diagnosing axillary lymph node metastasis. Br J Surg. 105(10):1244-1253, 2018 09.
103. [22227922] Valente SA, Levine GM, Silverstein MJ, et al. Accuracy of predicting axillary lymph node positivity by physical examination, mammography, ultrasonography, and magnetic resonance imaging. Ann Surg Oncol. 19(6):1825-30, 2012 Jun.
104. [29641226] Helal MH, Mansour SM, Salaleldin LA, Alkalaawy BM, Salem DS, Mokhtar NM. The impact of contrast-enhanced spectral mammogram (CESM) and three-dimensional breast ultrasound (3DUS) on the characterization of the disease extend in cancer patients. Br J Radiol. 91(1087):20170977, 2018 Jul.
105. [24780784] Appleton DC, Hackney L, Narayanan S. Ultrasonography alone for diagnosis of breast cancer in women under 40. Ann R Coll Surg Engl. 96(3):202-6, 2014 Apr.
106. [24596363] Mariscotti G, Houssami N, Durando M, et al. Accuracy of mammography, digital breast tomosynthesis, ultrasound and MR imaging in preoperative assessment of breast cancer. Anticancer Res. 34(3):1219-25, 2014 Mar.
107. [11015105] Hungness ES, Safa M, Shaughnessy EA, et al. Bilateral synchronous breast cancer: mode of detection and comparison of histologic features between the 2 breasts. Surgery 2000;128:702-7.
108. [7602346] Broet P, de la Rochefordiere A, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 1995;13:1578-83.
109. [28221238] Koh J, Kim EK, Kim MJ, Yoon JH, Moon HJ. Additional Magnetic Resonance Imaging-Detected Suspicious Lesions in Known Patients With Breast Cancer: Comparison of Second-Look Digital Tomosynthesis and Ultrasonography. ULTRASOUND Q.. 33(2):167-173, 2017 Jun.
110. [25119022] Spick C, Baltzer PA. Diagnostic utility of second-look US for breast lesions identified at MR imaging: systematic review and meta-analysis. Radiology 2014;273:401-9.
111. [16442946] Dillon MF, Hill AD, Fleming FJ, et al. Identifying patients at risk of compromised margins following breast conservation for lobular carcinoma. Am J Surg 2006;191:201-5.
112. [17574805] Mann RM, Veltman J, Barentsz JO, Wobbes T, Blickman JG, Boetes C. The value of MRI compared to mammography in the assessment of tumour extent in invasive lobular carcinoma of the breast. Eur J Surg Oncol 2008;34:135-42.
113. [30131246] Vijayaraghavan GR, Vedantham S, Santos-Nunez G, Hultman R. Unifocal Invasive Lobular Carcinoma: Tumor Size Concordance Between Preoperative Ultrasound Imaging and Postoperative Pathology. Clin Breast Cancer 2018;18:e1367-e72.
114. [16500539] Veltman J, Boetes C, van Die L, Bult P, Blickman JG, Barentsz JO. Mammographic detection and staging of invasive lobular carcinoma. Clin Imaging 2006;30:94-8.
115. [3814476] Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
116. [10963602] Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
117. [20498394] Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-7.
118. [11553815] Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874.
119. [21914172] Sihto H, Lundin J, Lundin M, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res. 13(5):R87, 2011 Sep 13.
120. [18451135] Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68:3108-14.
121. [23897954] Metzger-Filho O, Sun Z, Viale G, et al. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol 2013;31:3083-90.
122. [27083181] Liede A, Jerzak KJ, Hernandez RK, Wade SW, Sun P, Narod SA. The incidence of bone metastasis after early-stage breast cancer in Canada. Breast Cancer Res Treat 2016;156:587-95.
123. [28194227] Pulido C, Vendrell I, Ferreira AR, et al. Bone metastasis risk factors in breast cancer. Ecancermedicalscience 2017;11:715.
124. [1174812] Galasko CS. The significance of occult skeletal metastases, detected by skeletal scintigraphy, in patients with otherwise apparently 'early' mammary carcinoma. Br J Surg 1975;62:694-6.
125. [32950408] James J, Teo M, Ramachandran V, Law M, Ip E, Cheng M. Looking for Metastasis in Early Breast Cancer: Does Bone Scan Help? A Retrospective Review. Clin Breast Cancer 2021;21:e18-e21.
126. [-3195169] NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 4.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
127. [14672401] Gerber B, Seitz E, Muller H, et al. Perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread. Breast Cancer Res Treat 2003;82:29-37.
128. [-3195171] ABIM/ASCO Choosing Wisely. Imaging and tumor marker tests for breast cancer. When you need them—and when you don’t. Available at: https://www.choosingwisely.org/wp-content/uploads/2018/03/Imaging-And-Tumor-Marker-Tests-ASCO.pdf.
129. [30443868] Ayala de la Pena F, Andres R, Garcia-Saenz JA, et al. SEOM clinical guidelines in early stage breast cancer (2018). Clin Transl Oncol 2019;21:18-30.
130. [31236598] Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:1674.
131. [28596258] Dull B, Linkugel A, Margenthaler JA, Cyr AE. Overuse of Chest CT in Patients With Stage I and II Breast Cancer: An Opportunity to Increase Guidelines Compliance at an NCCN Member Institution. J. Natl. Compr. Cancer Netw.. 15(6):783-789, 2017 06.
132. [30797241] James J, Teo M, Ramachandran V, Law M, Stoney D, Cheng M. A critical review of the chest CT scans performed to detect asymptomatic synchronous metastasis in new and recurrent breast cancers. World J Surg Oncol. 17(1):40, 2019 Feb 23.
133. [34416711] Groheux D, Hindie E, Espie M, Ulaner GA. Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change? J Natl Compr Canc Netw 2021;19:xxx.
134. [32886897] Ko H, Baghdadi Y, Love C, Sparano JA. Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy. J. Natl. Compr. Cancer Netw.. 18(9):1240-1246, 2020 09.
135. [31907750] Srour MK, Amersi F. Response to Letter to the Editor: "18FDG-PET/CT Imaging in Breast Cancer Patients with Clinical Stage IIB or Higher". Ann Surg Oncol 2020;27:1710-11.
136. [23243198] Groheux D, Hindie E, Delord M, et al. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 104(24):1879-87, 2012 Dec 19.
137. [31063423] Ulaner GA. PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact? AJR Am J Roentgenol 2019;213:254-65.
138. [21880576] Groheux D, Giacchetti S, Espie M, et al. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med. 52(10):1526-34, 2011 Oct.
139. [28456837] Ulaner GA, Castillo R, Wills J, Gonen M, Goldman DA. 18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. European Journal of Nuclear Medicine & Molecular Imaging. 44(9):1420-1427, 2017 Aug.Eur J Nucl Med Mol Imaging. 44(9):1420-1427, 2017 Aug.
140. [20807849] Neal CH, Daly CP, Nees AV, Helvie MA. Can preoperative axillary US help exclude N2 and N3 metastatic breast cancer?. Radiology. 257(2):335-41, 2010 Nov.
141. [24008555] Diepstraten SC, Sever AR, Buckens CF, et al. Value of preoperative ultrasound-guided axillary lymph node biopsy for preventing completion axillary lymph node dissection in breast cancer: a systematic review and meta-analysis. [Review]. Ann Surg Oncol. 21(1):51-9, 2014 Jan.
142. [26834110] McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical Diagnosis and Management of Breast Cancer. J Nucl Med 2016;57 Suppl 1:9S-16S.
143. [15254062] Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. [Review] [100 refs]. J Clin Oncol. 22(14):2942-53, 2004 Jul 15.
144. [28786907] Bansal GJ, Vinayan Changaradil D. Planar Bone Scan Versus Computerized Tomography in Staging Locally Advanced Breast Cancer in Asymptomatic Patients: Does Bone Scan Change Patient Management Over Computerized Tomography?. J Comput Assist Tomogr. 42(1):19-24, 2018 Jan/Feb.
145. [22342788] Chu QD, Henderson A, Kim RH, et al. Should a routine metastatic workup be performed for all patients with pathologic N2/N3 breast cancer?. J Am Coll Surg. 214(4):456-61; discussion 461-2, 2012 Apr.
146. [23287962] Krammer J, Engel D, Schnitzer A, et al. Is the assessment of the central skeleton sufficient for osseous staging in breast cancer patients? A retrospective approach using bone scans. Skeletal Radiol. 42(6):787-91, 2013 Jun.
147. [27642105] Piatek CI, Ji L, Kaur C, et al. Value of routine staging imaging studies for patients with stage III breast cancer. J Surg Oncol. 114(8):917-921, 2016 Dec.
148. [27551013] Bychkovsky BL, Guo H, Sutton J, et al. Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer. Oncologist. 21(12):1495-1501, 2016 12.
149. [19645022] Alberini JL, Lerebours F, Wartski M, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer 2009;115:5038-47.
150. [19164229] Carkaci S, Macapinlac HA, Cristofanilli M, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 2009;50:231-8.
151. [23640467] Champion L, Lerebours F, Cherel P, et al. (1)(8)F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer. Eur J Nucl Med Mol Imaging 2013;40:1206-13.
152. [18695254] Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26:4746-51.
153. [18436392] Groheux D, Moretti JL, Baillet G, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008; 71(3):695-704.
154. [18632831] Heusner TA, Kuemmel S, Umutlu L, et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008;49:1215-22.
155. [25214641] Riedl CC, Slobod E, Jochelson M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 55(10):1578-83, 2014 Oct.
156. [21070439] Segaert I, Mottaghy F, Ceyssens S, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J. 16(6):617-24, 2010 Nov-Dec.
157. [27129866] Ulaner GA, Castillo R, Goldman DA, et al. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging 2016;43:1937-44.
158. [17653852] Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 2008;109:417-26.
159. [29313949] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a Cancer Journal for Clinicians. 68(1):7-30, 2018 01.
160. [20516453] Morris PG, Lynch C, Feeney JN, et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol. 28(19):3154-9, 2010 Jul 01.
161. [21765193] Niikura N, Costelloe CM, Madewell JE, et al. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist. 16(8):1111-9, 2011.
162. [-3111285] Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
163. [15254054] Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-72.
164. [17577662] Pelletier EM, Shim B, Goodman S, Amonkar MM. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat 2008;108:297-305.
165. [28301662] Martin AM, Cagney DN, Catalano PJ, et al. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. JAMA Oncol. 3(8):1069-1077, 2017 Aug 01.
166. [24799487] Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. [Review]. J Clin Oncol. 32(19):2100-8, 2014 Jul 01.
167. [2702564] Kurtz JM, Amalric R, Brandone H, et al. Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer 1989;63:1912-7.
168. [2841261] Recht A, Silen W, Schnitt SJ, et al. Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. Int J Radiat Oncol Biol Phys 1988;15:255-61.
169. [32442059] Buchholz TA, Ali S, Hunt KK. Multidisciplinary Management of Locoregional Recurrent Breast Cancer. J Clin Oncol 2020;38:2321-28.
170. [29723396] Valachis A, Mamounas EP, Mittendorf EA, et al. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. Cancer 2018;124:2923-30.
171. [18421576] Lu WL, Jansen L, Post WJ, Bonnema J, Van de Velde JC, De Bock GH. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat 2009;114:403-12.
172. [-3195173] NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. NCCN Evidence Blocks. Version 2.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf.
173. [-3195175] ASCO Guidelines. Breast Cancer Follow-Up And Management After Primary Treatment: American Society Of Clinical Oncology Clinical Practice Guideline Update. Available at: https://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/2013-breast-surveillance-summary-recommendations.pdf.
174. [22692036] Arasu VA, Joe BN, Lvoff NM, et al. Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy. Radiology. 264(2):371-7, 2012 Aug.
175. [22766990] Lewis JL, Tartter PI. The value of mammography within 1 year of conservative surgery for breast cancer. Ann Surg Oncol. 19(10):3218-22, 2012 Oct.
176. [27422453] Bychkovsky BL, Lin NU. Imaging in the evaluation and follow-up of early and advanced breast cancer: When, why, and how often?. [Review]. BREAST. 31:318-324, 2017 Feb.
177. [28341031] Benveniste AP, Dryden MJ, Bedrosian I, Morrow PK, Bassett RL Jr, Yang W. Surveillance of women with a personal history of breast cancer by tumour subtype. Clin Radiol. 72(3):266.e1-266.e6, 2017 Mar.
178. [27810132] Fung F, Cornacchi SD, Reedijk M, et al. Breast cancer recurrence following radioguided seed localization and standard wire localization of nonpalpable invasive and in situ breast cancers: 5-Year follow-up from a randomized controlled trial. Am J Surg. 213(4):798-804, 2017 Apr.
179. [23860534] Kraeima J, Siesling S, Vliegen IM, Klaase JM, IJzerman MJ. Individual risk profiling for breast cancer recurrence: towards tailored follow-up schemes. Br J Cancer. 109(4):866-71, 2013 Aug 20.
180. [30207076] Witteveen A, Otten JWM, Vliegen IMH, Siesling S, Timmer JB, IJzerman MJ. Risk-based breast cancer follow-up stratified by age. Cancer Medicine. 7(10):5291-5298, 2018 10.
181. [32966113] Chikarmane SA, Cochon LR, Khorasani R, Sahu S, Giess CS. Screening Mammography Performance Metrics of 2D Digital Mammography Versus Digital Breast Tomosynthesis in Women With a Personal History of Breast Cancer. AJR. American Journal of Roentgenology. 217(3):587-594, 2021 09.AJR Am J Roentgenol. 217(3):587-594, 2021 09.
182. [34003059] Lee JM, Ichikawa LE, Wernli KJ, et al. Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007-2016. Radiology. 300(2):290-300, 2021 08.
183. [26893205] McDonald ES, Oustimov A, Weinstein SP, Synnestvedt MB, Schnall M, Conant EF. Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography: Outcomes Analysis From 3 Years of Breast Cancer Screening. JAMA Oncology. 2(6):737-43, 2016 Jun 01.
184. [29748762] Lowry KP, Braunstein LZ, Economopoulos KP, et al. Predictors of surveillance mammography outcomes in women with a personal history of breast cancer. Breast Cancer Research & Treatment. 171(1):209-215, 2018 Aug.
185. [31453765] Sung JS, Lebron L, Keating D, et al. Performance of Dual-Energy Contrast-enhanced Digital Mammography for Screening Women at Increased Risk of Breast Cancer. Radiology. 2019 Oct;293(1):81-88.
186. [29371086] Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR. Journal of the American College of Radiology. 15(3 Pt A):408-414, 2018 03.
187. [26774742] Destounis S, Arieno A, Morgan R. Personal History of Premenopausal Breast Cancer as a Risk Factor for Referral to Screening Breast MRI. Acad Radiol. 23(3):353-7, 2016 Mar.
188. [31161975] Wernli KJ, Ichikawa L, Kerlikowske K, et al. Surveillance Breast MRI and Mammography: Comparison in Women with a Personal History of Breast Cancer. Radiology. 292(2):311-318, 2019 08.Radiology. 292(2):311-318, 2019 08.
189. [22474203] Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 307(13):1394-404, 2012 Apr 04.
190. [26142951] Giess CS, Poole PS, Chikarmane SA, Sippo DA, Birdwell RL. Screening Breast MRI in Patients Previously Treated for Breast Cancer: Diagnostic Yield for Cancer and Abnormal Interpretation Rate. Acad Radiol. 22(11):1331-7, 2015 Nov.
191. [24635678] Gweon HM, Cho N, Han W, et al. Breast MR imaging screening in women with a history of breast conservation therapy. Radiology. 272(2):366-73, 2014 Aug.
192. [26744477] Lehman CD, Lee JM, DeMartini WB, et al. Screening MRI in Women With a Personal History of Breast Cancer. Journal of the National Cancer Institute. 108(3), 2016 Mar.
193. [26322264] Weinstock C, Campassi C, Goloubeva O, et al. Breast magnetic resonance imaging (MRI) surveillance in breast cancer survivors. Springerplus 2015;4:459.
194. [28527397] Nadler M, Al-Attar H, Warner E, et al. MRI surveillance for women with dense breasts and a previous breast cancer and/or high risk lesion. BREAST. 34:77-82, 2017 Aug.
195. [29435556] Buist DSM, Abraham L, Lee CI, et al. Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Internal Medicine. 178(4):458-468, 2018 04 01.
196. [32303988] Haas CB, Nekhlyudov L, Lee JM, et al. Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis. Breast Cancer Research & Treatment. 181(2):255-268, 2020 Jun.
197. [23695431] Suh YJ, Kim MJ, Kim EK, Moon HJ, Kim SI, Park BW. Value of ultrasound for postoperative surveillance of asian patients with history of breast cancer surgery: a single-center study. Ann Surg Oncol. 20(11):3461-8, 2013 Oct.
198. [24959654] Scheel JR, Lee JM, Sprague BL, Lee CI, Lehman CD. Screening ultrasound as an adjunct to mammography in women with mammographically dense breasts. [Review]. Am J Obstet Gynecol. 212(1):9-17, 2015 Jan.
199. [30102208] Giannotti DG, Hanna SA, Cerri GG, Barbosa Bevilacqua JL. Analysis of Skin Flap Thickness and Residual Breast Tissue After Mastectomy. Int J Radiat Oncol Biol Phys. 102(1):82-91, 2018 09 01.
200. [-3195384] ESMO Interactive Guidelines. Available at: http://interactiveguidelines.esmo.org/esmo-web-app/toc/index.php?subjectAreaId=8.
201. [32374666] Chapman MC, Hayward JH, Woodard GA, Joe BN, Lee AY. The Role of Breast MRI in Detecting Asymptomatic Recurrence After Therapeutic Mastectomy. AJR Am J Roentgenol. 215(1):254-261, 2020 07.
202. [23345348] Brandt KR, Craig DA, Hoskins TL, et al. Can digital breast tomosynthesis replace conventional diagnostic mammography views for screening recalls without calcifications? A comparison study in a simulated clinical setting. AJR Am J Roentgenol 2013;200:291-8.
203. [30240292] Sorin V, Yagil Y, Yosepovich A, et al. Contrast-Enhanced Spectral Mammography in Women With Intermediate Breast Cancer Risk and Dense Breasts. AJR Am J Roentgenol. 2018 Nov;211(5):W267-W274.
204. [23046046] Olsen ML, Morton MJ, Stan DL, Pruthi S. Is there a role for magnetic resonance imaging in diagnosing palpable breast masses when mammogram and ultrasound are negative? J Womens Health (Larchmt) 2012;21:1149-54.
205. [28754486] Amitai Y, Menes TS, Weinstein I, Filyavich A, Yakobson I, Golan O. What is the yield of breast MRI in the assessment of palpable breast findings?. Clin Radiol. 72(11):930-935, 2017 Nov.
206. [32108973] Yalniz C, Campbell D, Le-Petross C, et al. The role of magnetic resonance imaging in patients with palpable breast abnormalities and negative mammographic and sonographic findings. Breast Journal. 26(7):1289-1295, 2020 07.
207. [28473077] Moy L, Heller SL, Bailey L, et al. ACR Appropriateness Criteria® Palpable Breast Masses. J Am Coll Radiol 2017;14:S203-S24.
208. [30392596] Holbrook AI, Moy L, Akin EA, et al. ACR Appropriateness Criteria® Breast Pain. J Am Coll Radiol 2018;15:S276-S82.
209. [23601761] Lin NU, Thomssen C, Cardoso F, et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. BREAST. 22(3):203-10, 2013 Jun.
210. [26314782] Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 26 Suppl 5:v8-30, 2015 Sep.
211. [31685104] Whitehead MT, Cardenas AM, Corey AS, et al. ACR Appropriateness Criteria® Headache. J Am Coll Radiol 2019;16:S364-S77.
212. [-3128692] American College of Radiology. ACR Appropriateness Criteria® Radiation Dose Assessment Introduction. Available at: https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/Clinical/Appropriateness-Criteria/ACR-Appropriateness-Criteria-Radiation-Dose-Assessment-Introduction.pdf.